- Our experience with the treatment of lanreotide in combination with everolimus in the treatment of Merkel cell carcinoma2013 | Publication without faculty affiliation
- Everolimus in the treatment of metastatic renal cell cancer2014 | First Faculty of Medicine
- Everolimus 2nd line palliative biotherapy in a patient with metastatic renal cell cancer with clinically significant manifestation of paraneoplastic polyglobulia2013 | Publication without faculty affiliation
- m-TOR associated stomatitis in everolimus treatment and significant prophylactic effect of dexamethasone solution in context of Bolero-2 and SWISH trials2017 | Faculty of Medicine in Pilsen
- Everolimus in therapy of lung and gastrointestinal neuroendocrine tumors - comments on Radiant-42017 | First Faculty of Medicine
- Metastatic Renal Cell Carcinoma Treated with Everolimus – Data from the RENIS Clinical Registry2011 | First Faculty of Medicine
- M TOR inhibitor everolimus in patients in with autosomal dominant polycystic kidney disease.Commentary on:NEJM 363,20102010 | First Faculty of Medicine
- Management of metabolic adverse effects of everolimus in patients with renal carcinoma2019 | First Faculty of Medicine
- Everolimus in daily clinical practice focusing to oral mucosa damage issues - single oncology centre experience within the course of the year 20162017 | Faculty of Medicine in Pilsen
- VEGFREverolimus in the treatment of metastatic renal cell carcinoma - subanalysis of patients from the RECORD-1 study pretreated with one vs. two VEGFR inhibitors2012 | Second Faculty of Medicine
- Everolimus v léčbě karcinomu prsu2015 | First Faculty of Medicine
- Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis2014 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Pilsen
- Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial2018 | Faculty of Medicine in Hradec Králové
- EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex2016 | Second Faculty of Medicine
- Absorb Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent in ST-Segment Elevation Myocardial Infarction: 1-Year Results of a Propensity Score Matching Comparison The BVS-EXAMINATION Study (Bioresorbable Vascular Scaffold-A Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients With ST-segment Elevation Myocardial Infarction)2015 | Third Faculty of Medicine
- Renal cell carcinoma 20152015 | First Faculty of Medicine
- The SPIRIT V study: a clinical evaluation of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions2011 | Faculty of Medicine in Hradec Králové
- Dlouhodobé použití everolimu u pacientů s tuberózní sklerózou - čtyřleté sledování, otevřené pokračování studie EXIST 2: komentář2017 | First Faculty of Medicine
- The current view on the treatment of neuroendocrine tumours2015 | First Faculty of Medicine
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma2015 | Publication without faculty affiliation
- How to proceed in the treatment of metastatic renal cell carcinoma?2015 | First Faculty of Medicine
- ABSORB bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in ST-segment elevation myocardial infarction (BVS EXAMINATION study): 2-Year results from a propensity score matched comparison2016 | Third Faculty of Medicine
- Systemic treatment of renal cell carcinoma and news in 20142014 | First Faculty of Medicine
- Biological treatment of renal cell cancer2012 | First Faculty of Medicine
- RECORD-4: multicentrická studie fáze II hodnotící everolimus (EVE) v druhé linii léčby pacientů s metastazujícím karcinomem ledviny (mRCC)2015 | First Faculty of Medicine
- Bioresorbable vascular scaffolds versus everolimus-eluting metallic stents in patients with ST-segment elevation myocardial infarction: 5-year results of the BVS-EXAMINATION study2020 | Third Faculty of Medicine
- Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry2017 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Faculty of Medicine in Pilsen
- Comparison of a Bioresorbable, Magnesium-Based Sirolimus-Eluting Stent with a Permanent, Everolimus-Eluting Metallic Stent for Treating Patients with Acute Coronary Syndrome: the PRAGUE-22 Study2022 | Third Faculty of Medicine, Central Library of Charles University
- News in the systemic treatment of advanced kidney cancer2016 | Publication without faculty affiliation
- Impact of BOLERO-2 study results on clinical practice and future treatment of postmenopausal patients with advance HR+/HER2- breast cancer2014 | First Faculty of Medicine
